» Articles » PMID: 39766591

Dynamic PK/PD Infection Models for the Development and Optimisation of Antimicrobial Regimens: A Narrative Review

Overview
Specialty Pharmacology
Date 2025 Jan 8
PMID 39766591
Authors
Affiliations
Soon will be listed here.
Abstract

The antimicrobial concentration-time profile in humans affects antimicrobial activity, and as such, it is critical for preclinical infection models to simulate human-like dynamic concentration-time profiles for maximal translatability. This review discusses the setup, principle, and application of various dynamic PK/PD infection models commonly used in the development and optimisation of antimicrobial treatment regimens. It covers the commonly used dynamic infection models, including the one-compartment model, hollow fibre infection model, biofilm model, bladder infection model, and aspergillus infection model. It summarises the mathematical methods for the simulation of the pharmacokinetic profile of single or multiple antimicrobials when using the serial or parallel configurations of systems. Dynamic models offer reliable pharmacokinetic/pharmacodynamic data to help define the initial dosing regimens of new antimicrobials that can be developed further in clinical trials. They can also help in the optimisation of dosing regimens for existing antimicrobials, especially in the presence of emerging antimicrobial resistance. In conclusion, dynamic infection models replicate the interactions that occur between microorganisms and dynamic antimicrobial exposures in the human body to generate data highly predictive of the clinical efficacy. They are particularly useful for the development new treatment strategies against antimicrobial-resistant pathogens.

References
1.
NAVASHIN S, FOMINA I, Firsov A, CHERNYKH V, Kuznetsova S . A dynamic model for in-vitro evaluation of antimicrobial action by simulation of the pharmacokinetic profiles of antibiotics. J Antimicrob Chemother. 1989; 23(3):389-99. DOI: 10.1093/jac/23.3.389. View

2.
Lora-Tamayo J, Murillo O, Bergen P, Nation R, Poudyal A, Luo X . Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. J Antimicrob Chemother. 2014; 69(9):2434-42. DOI: 10.1093/jac/dku151. View

3.
Al-Saigh R, Elefanti A, Velegraki A, Zerva L, Meletiadis J . In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model. Antimicrob Agents Chemother. 2012; 56(10):5321-7. PMC: 3457389. DOI: 10.1128/AAC.00549-12. View

4.
VanScoy B, Mendes R, Castanheira M, McCauley J, Bhavnani S, Forrest A . Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother. 2013; 57(9):4134-8. PMC: 3754319. DOI: 10.1128/AAC.00461-13. View

5.
Kembou-Ringert J, Readman J, Smith C, Breuer J, Standing J . Applications of the hollow-fibre infection model (HFIM) in viral infection studies. J Antimicrob Chemother. 2022; 78(1):8-20. PMC: 9780528. DOI: 10.1093/jac/dkac394. View